SCHEMBL30857710

SCHEMBL30857710

CC(C)(C)[Si](OCC[C@H]1CN(Cc2ccccc2)CCN1)(c1ccccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.48
SMYD2 Q9NRG4 3/20 0.39
SIGMAR1 Q99720 1/20 0.38
CYP3A4 P08684 3/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
CXCR4 P61073 2/20 0.35
TACR1 P25103 1/20 0.35
CYP2C19 P33261 2/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 1/20 0.34
ACHE P22303 1/20 0.34
CYP2D6 P10635 1/20 0.34
ALDH1A1 P00352 1/20 0.34
DRD4 P21917 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29246127 0.80 SMYD2 (0.41) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL16433235 0.80 LTA4H (0.48) LTA4HSIGMAR1CYP3A4CXCR4TACR1
SCHEMBL16432291 0.80 LTA4H (0.48) LTA4HSIGMAR1CYP3A4CXCR4TACR1
SCHEMBL24803467 0.80 LTA4H (0.57) LTA4HSIGMAR1CYP3A4CYP2C19CYP1A2
SCHEMBL13308369 0.80 LTA4H (0.57) LTA4HSIGMAR1CYP3A4CYP2C19CYP1A2
SCHEMBL6731676 0.79 LMNA (0.50) SIGMAR1ALDH1A1
SCHEMBL16439837 0.77 LTA4H (0.52) LTA4HSIGMAR1CYP3A4CXCR4CYP2C19
SCHEMBL5077219 0.77 LTA4H (0.58) LTA4HSIGMAR1CYP3A4CXCR4TACR1
SCHEMBL19617349 0.77 MAPK1 (0.40) SMYD2CYP3A4HTTSMN1; SMN2
SCHEMBL30927563 0.77 MAPK1 (0.40) SMYD2CYP3A4HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024067818-A1 CHIMERIC COMPOUND USED FOR TARGETED DEGRADATION OF BCL-2 PROTEIN, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF 江苏恒瑞医药股份有限公司 2024-04-04 WO disclosed